Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10340531 | 0.94 | TSHR (0.33) | TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL7861963 | 0.94 | TSHR (0.33) | TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL7861964 | 0.94 | TSHR (0.33) | TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL10340530 | 0.94 | TSHR (0.33) | TSHRCYP2C19MEN1KMT2A | |
| Nitric Acid SCHEMBL5697157 | 0.87 | CA5A (0.38) | TSHRCYP2C19 | |
| Nitric Acid SCHEMBL5697160 | 0.84 | CA5A (0.40) | TSHRCYP2C19 | |
| SCHEMBL29738285 | 0.82 | — | — | |
| SCHEMBL8672905 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL20291779 | 0.78 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL261336 | 0.78 | TSHR (0.38) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975329-B1 | LIPID COMPLEXES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | UPJOHN CO (US) | 2004-12-08 | — | — | EP | claimed |
| CN-1096263-C | Lipid complexes and liposomes of highly insoluble platinum complexes | UPJOHN CO (US) | 2002-12-18 | — | — | CN | claimed |
| US-6287593-B2 | ANTICANCER | PHARMACIA & UPJOHN (IT) | 2001-09-11 | — | — | US | claimed |
| CN-120192347-A | Compound for treating oxaliplatin resistant tumors, preparation method, composition and application thereof | 天津谷堆生物医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2023169433-A1 | POLYMER-COATED NANOPARTICLES AND PREPARATION METHOD THEREFOR | 晟迪生物医药(苏州)有限公司 | 2023-09-14 | — | — | WO | disclosed |
| EP-1705254-A2 | Compositions and methods using platinum for nucleic acid labeling | Stratagene California (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1373572-B1 | COMPOSITIONS AND METHODS USING PLATINUM COMPOUNDS FOR NUCLEIC ACID LABELING | STRATAGENE CALIFORNIA (US) | 2006-07-26 | — | — | EP | disclosed |
| CN-1191067-C | Lipid composition of high non-soluble platinum matches and lipid body | PAMACIA & UPJOHN CO (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-0975329-B1 | LIPID COMPLEXES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | UPJOHN CO (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6825330-B2 | A PLATINUM COMPOUND COVELENTLY ATTACHED TO A DETACTABLE MARKER VIA A LINKER (LINKER IS A GROUP JOINING NITROGEN TO A FLUOROPHORE, A CHROMOPHORE, A RADIOLABEL, AN ENZYME OR AN AFFINITY TAG) | STRATAGENE CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| CN-1422619-A | Lipid composition of high non-soluble platinum matches and lipid body | PAMACIA & UPJOHN CO (US) | 2003-06-11 | — | — | CN | disclosed |
| CN-1096263-C | Lipid complexes and liposomes of highly insoluble platinum complexes | UPJOHN CO (US) | 2002-12-18 | — | — | CN | disclosed |
| US-20020165369-A1 | Compositions and methods using platinum compounds for nucleic acid labeling | STRATAGENE | 2002-11-07 | — | — | US | disclosed |
| US-6287593-B2 | ANTICANCER | PHARMACIA & UPJOHN (IT) | 2001-09-11 | — | — | US | disclosed |
| US-20010010822-A1 | LIPID COMPLEXES AND LIPOSOMES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | CHERIAN MATHEW (IT) | 2001-08-02 | — | — | US | disclosed |
| CN-1264295-A | Lipid complexes and liposomes of highly insoluble platinum complexes | UPJOHN CO (US) | 2000-08-23 | — | — | CN | disclosed |
| EP-0975329-A1 | LIPID COMPLEXES AND LIPOSOMES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | PHARMACIA & UPJOHN COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998033481-A1 | LIPID COMPLEXES AND LIPOSOMES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165369-A1 | Compositions and methods using platinum compounds for nucleic acid labeling | PCNA, CXCR3, APEX1 | TSHR 2322/4885CYP2C19 4773/4885MEN1 2246/4885 |
| US-20010010822-A1 | LIPID COMPLEXES AND LIPOSOMES OF HIGHLY INSOLUBLE PLATINUM COMPLEXES | PHOSPHO1, LIPA, DLD | TSHR 4191/4885CYP2C19 3623/4885MEN1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.